Pre-Treatment Ki67 Index for Everolimus Efficacy in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter Cohort Study
The Ki67 cut-off value of 40% was identified as an optimal index for predicting the efficacy of everolimus, which may help with the management of everolimus in Chinese patients with HR+/HER2- ABC.
Authors
- Hanfang Jiang (ORCID: https://orcid.org/0000-0002-3502-7073)
- Binghe Xu
- Fei Ma
- Ying Fan
- Jiayu Wang
- Weihong Zhao
- Pin Zhang
- Yujing Tan
- Bo Lan
- Yang Luo
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Chinese PLA General Hospital (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2026-01-14
- DOI
- https://doi.org/10.4143/crt.2025.506
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences